Nebula Research & Development LLC Sells 3,905 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Nebula Research & Development LLC cut its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 16.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,360 shares of the biopharmaceutical company’s stock after selling 3,905 shares during the quarter. Nebula Research & Development LLC’s holdings in Xenon Pharmaceuticals were worth $798,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in XENE. Lord Abbett & CO. LLC grew its position in shares of Xenon Pharmaceuticals by 12.1% in the 4th quarter. Lord Abbett & CO. LLC now owns 194,971 shares of the biopharmaceutical company’s stock valued at $7,643,000 after acquiring an additional 20,986 shares during the period. Voya Investment Management LLC lifted its stake in Xenon Pharmaceuticals by 32.3% in the 4th quarter. Voya Investment Management LLC now owns 62,415 shares of the biopharmaceutical company’s stock valued at $2,447,000 after purchasing an additional 15,250 shares during the last quarter. Eversept Partners LP bought a new position in Xenon Pharmaceuticals during the fourth quarter worth about $6,097,000. J. Safra Sarasin Holding AG acquired a new position in Xenon Pharmaceuticals during the fourth quarter worth approximately $697,000. Finally, Affinity Asset Advisors LLC raised its stake in Xenon Pharmaceuticals by 1.5% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,161,237 shares of the biopharmaceutical company’s stock valued at $45,520,000 after buying an additional 17,216 shares during the period. 95.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on XENE shares. Royal Bank of Canada reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. StockNews.com raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $56.78.

Xenon Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ:XENE opened at $37.62 on Monday. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $46.00. The company’s 50 day moving average price is $34.80 and its two-hundred day moving average price is $38.66. The firm has a market cap of $2.88 billion, a PE ratio of -13.34 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.05. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.